Biosimilar companies chasing Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster complement C5 inhibitor are already facing up to the originator switching patients to next-generation product Ultomiris (ravulizumab-cwvz), ahead of potential US market formation in 2025.
Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle
New Rapid Infusion Formulation Bolsters Originator
Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).
